Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential efgartigimod followed by telitacicept in generalized myasthenia gravis
ChiCTR2400084781Phase 2Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- May 2024
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of efgartigimod alfa and telitacicept in myasthenia gravis (MG), sponsored by Peking University People's Hospital. Primary endpoints: Change in QMG score from baseline at Week 24, Change in MG-ADL score from baseline at Week 24 and 1 more. Planned start May 2024; status: not yet recruiting.
02
Drugs
efgartigimod alfatelitacicept
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR2400084781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084781.